Health

Transactions in connection with share buy-back program

Company announcement no. 10 - 2614 April 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG…

2 weeks ago

Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative personalized off-the-shelf immunotherapy toward clinical development

April 14, 2026 03:30 ET  | Source: Asgard Therapeutics Medical oncologist (ex AstraZeneca, MorphoSys, Autolus Therapeutics) joins to advance Asgard’s…

2 weeks ago

EmPRO Reports Another Year of Strong Financial Results with Significant Growth in Net Income and Surplus During 2025

ROSLYN, N.Y., April 13, 2026 (GLOBE NEWSWIRE) -- EmPRO Insurance Company (EmPRO), a licensed medical professional liability insurance carrier serving…

2 weeks ago

Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026

April 13, 2026 09:00 ET  | Source: Senti Biosciences, Inc. SOUTH SAN FRANCISCO, Calif., April 13, 2026 (GLOBE NEWSWIRE) --…

2 weeks ago

Switchback Medical Signs Lease for 18,000 Square Foot Facility in Costa Ricas Coyol Free Trade Zone

BROOKLYN PARK, MN, April 13, 2026 (GLOBE NEWSWIRE) -- Switchback Medical, a medical device contract development and manufacturing organization (CDMO),…

2 weeks ago

Glo & Spa-rkle Aesthetics and Medical Spa Unveils New State-of-the-Art Location in Lubbock, Texas

Join the Grand Opening Celebration on May 1, 2026, for an Evening of Beauty and Innovation April 10, 2026 19:12…

2 weeks ago

Pelthos Therapeutics Announces CFO Transition

Senior Vice President, Finance & Accounting John M. Gay named Chief Financial Officer April 10, 2026 17:00 ET  | Source:…

2 weeks ago

Mesoblast Receives IND Clearance From FDA to Directly Proceed to Registrational Trial for Approval of Ryoncil in Duchenne Muscular Dystrophy – CORRECTION

April 10, 2026 16:09 ET  | Source: Mesoblast Limited Working with Parent Project Muscular Dystrophy and the Duchenne Registry on…

2 weeks ago

BioNTech and DualityBios Antibody-Drug Conjugate Trastuzumab Pamirtecan Demonstrated Clinically Meaningful Efficacy in Patients with HER2-Expressing, Recurrent Endometrial Cancer

Trastuzumab pamirtecan, an investigational HER2-targeted antibody-drug conjugate, met the primary efficacy endpoint in a Phase 2 cohort of heavily pre-treated…

2 weeks ago

NeuroSalt Under Investigation: What the 2026 Formulation Transparency Review Reveals About Botanical Ingredients, Dosage Disclosure, and Consumer Verification

Largo, FL, April 10, 2026 (GLOBE NEWSWIRE) -- A commission may be earned if you purchase through links in this…

2 weeks ago